NCT06714448Completed
A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
Post Authorization Safety Study Assessing the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia. The end of study is defined as the end of the data collection period. No intervention will be administered, and no study related visits are required.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 455 (actual)
- First submitted
- 27 Nov 2024
- Start date
- 29 Apr 2025
- Primary completion date
- 22 Sept 2025
- Lead sponsor
- Sanofi
- Diseases
- Epilepsy
- NCT number
- NCT06714448
What you commit to
- Study type: Observational
- Participants enrolled: 455
- From 29 Apr 2025 to the primary completion date, 22 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome
Lab values
- Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® \[sodium valproate\])
- Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion
- The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Other
- Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies)
Who the study is looking for
- Healthcare professionals working only in Saudi Arabia AND
- Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR
- Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR
- Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sanofi-Aventis Coordinator of this site? Confirm its status | Chilly-Mazarin | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.